Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Cisplatin, Durvalumab Alternating With Pemigatinib in Advanced Biliary Tract Cancers
NCT07780838Phase 2Recruiting
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Nov 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, Cisplatin micelle injection (HA132), durvalumab, pemigatinib in biliary tract cancer (BTC), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Started Nov 2026; status: recruiting.
02
Drugs
gemcitabineCisplatin micelle injection (HA132)durvalumabpemigatinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07780838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07780838.